Insmed Incorporated (LSX:A1JJA3) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$750M · US$96 a share · Goldman Sachs & Co. LLC +5 Dealers: Goldman Sachs & Co. LLC (lead), Leerink Partners (lead), BofA Securities (lead), Jefferies (lead), J.P. Morgan (lead), Stifel (co-lead) Use of proceeds: R&D and commercialization of brensocatib, ARIKAYCE commercialization and development, TPIP, INS1201 and pre-clinical research, and general corporate purposes | Jun 11, 2025 |
| Public offering of common stock Announced: US$650M · Goldman Sachs & Co. LLC +1 Dealers: Goldman Sachs & Co. LLC (co-lead), Leerink Partners (co-lead) | Jun 11, 2025 |